Special Issue "Cancer Immunotherapy and Vaccination: Mechanistic Insights into Lymphocyte-Mediated Immune Modulation"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 31 December 2022 | Viewed by 1004

Special Issue Editor

Dr. Jianmei Leavenworth
E-Mail Website
Guest Editor
Heersink School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL 35233, USA
Interests: tumor immunology; cancer vaccines; cancer immunotherapy; oncolytic virotherapy; T cells; NK cells; tumor-associated macrophages

Special Issue Information

Dear Colleagues,

Cancer remains a major public health and economic issue with an ever-increasing burden. The advancement of cancer vaccines and immunotherapies, including checkpoint inhibitors and oncolytic virotherapy, that are able to amplify the body’s immune system against cancer has shown great promise. However, many human cancers fail to respond to these regimens due to the body’s own immunosuppressive tumor-promoting mechanisms that represent critical barriers to effective anti-tumor immunotherapies and vaccination. These mechanisms include the presence of immunosuppressive cells, e.g., regulatory T-cells, and dysfunctional effector cells that fail to exert anti-tumor activity in the tumor microenvironment. Moreover, some tumors even lack significant infiltration of anti-tumor effector cells, particularly cytotoxic T-cells and natural killer (NK) cells, rendering them resistant to immunotherapy. In addition to the required induction of anti-tumor cellular responses, recent studies have also begun to appreciate the necessity to enhance B-cell-mediated humoral antibody responses and to induce the formation of tertiary lymphoid structure in the tumor in order to improve the overall efficacy of cancer vaccines and immunotherapeutic approaches.

This Special Issue aims to provide a platform to all scientists working in these fields to discuss the currently known and any new mechanisms underlying the immune modulation induced by any developed or new cancer vaccines and immunotherapeutic approaches, with a focus on the immune responses driven by lymphocytes, including T-cells, B-cells, NK and innate lymphoid cells (ILC).

I look forward to receiving your contributions.

Dr. Jianmei Leavenworth
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.



  • tumor immunology
  • cancer immunotherapy
  • cancer vaccines
  • tumor microenvironment
  • CD4+ T-cells
  • regulatory T-cells
  • CD8+ T-cells
  • NK cells
  • innate lymphoid cells
  • cellular response
  • humoral response
  • tertiary lymphoid structure

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Genetic Modification of T Cells for the Immunotherapy of Cancer
Vaccines 2022, 10(3), 457; https://doi.org/10.3390/vaccines10030457 - 16 Mar 2022
Viewed by 832
Immunotherapy is a beneficial treatment approach for multiple cancers, however, current therapies are effective only in a small subset of patients. Adoptive cell transfer (ACT) is a facet of immunotherapy where T cells targeting the tumor cells are transferred to the patient with [...] Read more.
Immunotherapy is a beneficial treatment approach for multiple cancers, however, current therapies are effective only in a small subset of patients. Adoptive cell transfer (ACT) is a facet of immunotherapy where T cells targeting the tumor cells are transferred to the patient with several primary forms, utilizing unmodified or modified T cells: tumor-infiltrating lymphocytes (TIL), genetically modified T cell receptor transduced T cells, and chimeric antigen receptor (CAR) transduced T cells. Many clinical trials are underway investigating the efficacy and safety of these different subsets of ACT, as well as trials that combine one of these subsets with another type of immunotherapy. The main challenges existing with ACT are improving clinical responses and decreasing adverse events. Current research focuses on identifying novel tumor targeting T cell receptors, improving safety and efficacy, and investigating ACT in combination with other immunotherapies. Full article
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Back to TopTop